Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. - Wikidata - wikimedia - TriplyDB

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

http://www.wikidata.org/entity/Q40622941

about

Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90 A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication Hepatitis C virus proteins Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Chaperones in hepatitis C virus infection Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy Curing a viral infection by targeting the host: the example of cyclophilin inhibitors NTCP and beyond: opening the door to unveil hepatitis B virus entry Challenges of recurrent hepatitis C in the liver transplant patient Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro Studying Hepatitis C Virus: Making the Best of a Bad Virus Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro A Locking Mechanism Regulates RNA Synthesis and Host Protein Interaction by the Hepatitis C Virus Polymerase Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A Management of psoriasis patients with hepatitis B or hepatitis C virus infection Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A VAPC, an human endogenous inhibitor for hepatitis C virus (HCV) infection, is intrinsically unstructured but forms a "fuzzy complex" with HCV NS5B.Isoform-specific inhibition of cyclophilins Outcomes of kidney transplantation in HIV-infected recipients

P2860

Q21135500-E208094D-B05A-42D0-A64A-C133D64C300C Q21560973-3FD305BE-FBAC-4EB1-9A70-1BA2EA810B2B Q24305040-60316B15-D86D-47BF-8A3E-7A5C96322E34 Q24306116-6F618983-DF76-4965-88F1-D4C289207E85 Q24307609-3A7A4B7B-AA7B-4DFE-972E-8311CC0F7F54 Q24563969-0AC29EB4-8106-4C1D-B1C3-ABF223637C9C Q24645702-6B916F28-A26C-40BB-8686-31048154FC1A Q24656023-14A7AEE2-235B-473D-953D-C0C8D1A1D8BF Q26771251-FAFD05FD-66A6-4987-B5C2-C7FAF079B6FD Q26801207-FF6FCC14-CC60-41EB-BA0A-C247ECBC7D30 Q26828727-88888063-8070-4EBD-BAB1-14E5DE38AEBD Q26999712-C7079166-A163-4AD4-ABA1-7E06DA7ABB16 Q27011871-F99AA5D4-368C-4D15-93A1-EB8951AAF450 Q27468931-98FAE1D7-D229-4F60-82F4-A7205418BD05 Q27472822-1EB47C2E-1645-49E0-A801-11202FE20DD3 Q27473218-DAEBB7D3-DE5B-4DF0-869E-D1585D11BDE9 Q27477455-869E2726-A333-4668-BC5E-4F7262099E1E Q27480270-0459F49F-1FF0-4EAC-9FFF-D0B2A62604D7 Q27480361-64D3D256-0889-4B84-AA45-D09BFB1EDF75 Q27481034-EAB86B2D-9D02-4CC0-80DF-A88F1C5B6857 Q27486118-CBFAF10F-1660-41A1-B781-780D9577CA4C Q27486419-AF913004-F391-40B0-8496-E4500FBE6F17 Q27486813-71BC1448-A3A7-4B19-9E53-7DBEFF02574B Q27486821-C6363C8D-A9CA-4072-824C-3ABAAE84735E Q27488216-656549A9-4559-427F-A3F6-607BD5FC8580 Q27488369-C51DAA97-BD34-4299-A5DE-6C66DD2F4469 Q27488788-950FE9D0-8053-429C-9F90-B28C0DB5D5E3 Q27488982-A011E3AE-0A4C-4273-B5DA-E8E6452A9597 Q27489037-A6E65F37-6B2A-45EF-8169-BC451439924C Q27489053-E93F2623-5020-4125-87A4-5110C47662E7 Q27489369-2A3BECA3-2FE7-48A3-866C-76641B184BBE Q27490844-90893B7E-F333-4AAE-BDB3-A2DE511A665F Q27491288-4D9C1622-3761-4396-8495-46D0DD4C5B1A Q27491303-80BD9E9D-AC94-43A3-87CA-2A85B31DB885 Q28078157-34BC05CF-3BAD-4EF1-943A-F13AFE1E9E20 Q28483731-C3F30BAF-4F55-41F8-91BD-FEF3DE365676 Q28748683-EDBA6A91-588C-4865-9E3D-173D052DD703 Q30155273-C678BFA5-0494-4193-8755-2BA98B967022 Q30319101-E4CF0B19-9059-4E8E-B973-738EB261AA79 Q30432292-7D1AF244-A61A-48AD-B4B5-70B77337EC1C

P2860

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

http://www.wikidata.org/entity/Q40622941

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

@en

type

label

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

@en

prefLabel

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

@en

P1433

Q40622941-68886B88-CD13-4F89-B710-8081C08C0F18

P1476

Q40622941-4B4E9BAF-DC94-4DCC-BB34-7EBFA9280337

P2093

Q40622941-437C4B0D-B25D-4608-BFE3-37AA9D9D51FB

Q40622941-6E427FE2-D6BD-4DB5-A9F8-F19D419C5C04

Q40622941-84C085F3-08A5-4596-9E5F-493E45A6F548

Q40622941-AC4C444B-9782-4A87-A7FD-E521CE67192D

Q40622941-ED921B39-CD6E-4ED6-ADFD-60D681AC5DE8

P304

Q40622941-531462DC-8FB4-4709-94D4-036AE3F43625

P31

Q40622941-77BE7AED-0FAC-45C6-80CF-95F631678B1A

P356

Q40622941-D9067ABA-F047-43BF-AE3B-44181B9C941E

P407

Q40622941-DD9E44FD-9597-4AD0-97B7-A4E14EAA3E8E

P433

Q40622941-50049DD9-90DD-4919-85BB-C1DE27470FC2

P478

Q40622941-7F3305A4-898B-457C-992C-2B59C49287AB

P577

Q40622941-B783D653-FE11-4488-BE76-25E8C3B9A26D

P5875

Q40622941-DC3CB19C-63BB-4ADB-A64A-9CF6EE392852

P698

Q40622941-29C5D79C-C349-4758-9685-09A831CE357F

P356

JHEP.2003.50449

P1433

P1476

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

@en

P2093

Koichi Watashi

http://www.w3.org/2001/XMLSchema#string

Kunitada Shimotohno

http://www.w3.org/2001/XMLSchema#string

Makoto Hijikata

http://www.w3.org/2001/XMLSchema#string

Masahiro Hosaka

http://www.w3.org/2001/XMLSchema#string

Masashi Yamaji

http://www.w3.org/2001/XMLSchema#string

P304

1282-1288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2003.50449

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9039772

http://www.w3.org/2001/XMLSchema#string

P698

14578868

http://www.w3.org/2001/XMLSchema#string